NPM-ALK mediates phosphorylation of MSH2 at tyrosine 238, creating a functional deficiency in MSH2 and the loss of mismatch repair

Blood Cancer Journal - Tập 5 Số 5 - Trang e311-e311
Kathleen M. Bone1, P Wang1, Fang Wu1, Chenming Wu1, L Li1, Julinor Bacani1, Susan E. Andrew2, Rai‐Hua Lai3
1Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada
2Department of Medical Genetics, University of Alberta, Edmonton, Alberta, Canada
3Department of Oncology, University of Alberta, Edmonton, Alberta, Canada

Tóm tắt

AbstractThe vast majority of anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK+ALCL) tumors express the characteristic oncogenic fusion protein NPM-ALK, which mediates tumorigenesis by exerting its constitutive tyrosine kinase activity on various substrates. We recently identified MSH2, a protein central to DNA mismatch repair (MMR), as a novel binding partner and phosphorylation substrate of NPM-ALK. Here, using liquid chromatography–mass spectrometry, we report for the first time that MSH2 is phosphorylated by NPM-ALK at a specific residue, tyrosine 238. Using GP293 cells transfected with NPM-ALK, we confirmed that the MSH2Y238F mutant is not tyrosine phosphorylated. Furthermore, transfection of MSH2Y238F into these cells substantially decreased the tyrosine phosphorylation of endogenous MSH2. Importantly, gene transfection of MSH2Y238F abrogated the binding of NPM-ALK with endogenous MSH2, re-established the dimerization of MSH2:MSH6 and restored the sensitivity to DNA mismatch-inducing drugs, indicative of MMR return. Parallel findings were observed in two ALK+ALCL cell lines, Karpas 299 and SUP-M2. In addition, we found that enforced expression of MSH2Y238F into ALK+ALCL cells alone was sufficient to induce spontaneous apoptosis. In conclusion, our findings have identified NPM-ALK-induced phosphorylation of MSH2 at Y238 as a crucial event in suppressing MMR. Our studies have provided novel insights into the mechanism by which oncogenic tyrosine kinases disrupt MMR.

Từ khóa


Tài liệu tham khảo

Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES . The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011; 117: 5019–5032.

Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263: 1281–1284.

Pearson JD, Lee JK, Bacani JT, Lai R, Ingham RJ . NPM-ALK: the prototypic member of a family of oncogenic fusion tyrosine kinases. J Signal Transduct 2012; 2012: 123253.

Young LC, Bone KM, Wang P, Wu F, Adam BA, Hegazy S et al. Fusion tyrosine kinase NPM-ALK deregulates MSH2 and suppresses DNA mismatch repair function: novel insights into a potent oncoprotein. Am J Pathol 2011; 179: 411–421.

Li GM . Mechanisms and functions of DNA mismatch repair. Cell Res 2008; 18: 85–98.

Kunkel TA, Erie DA . DNA mismatch repair. Annu Rev Biochem 2005; 74: 681–710.

Sehgal R, Sheahan K, O'Connell PR, Hanly AM, Martin ST, Winter DC . Lynch syndrome: an updated review. Genes (Basel) 2014; 5: 497–507.

Krskova-Honzatkova L, Cermak J, Sajdova J, Stary J, Sedlacek P, Sieglova Z . Microsatellite instability in hematological malignancies. Leuk Lymphoma 2002; 43: 1979–1986.

Nkomdedeu JF, Perea G, Estivill C, Lasa A, Carnicer MJ, Brunet S et al. Microsatellite instability is not an uncommon finding in adult de novo acute myeloid leukemia. Ann Hematol 2005; 84: 368–375.

Degroote A, Knippenberg L, Vander Borght S, Spaepen M, Matthijs G, Schaeffer DF et al. Analysis of microsatellite instability in gastric mucosa-associated lymphoid tissue lymphoma. Leuk Lymphoma 2013; 54: 812–818.

Miyashita K, Fujii K, Yamada Y, Hattori H, Taguchi K, Yamanaka T et al. Frequent microsatellite instability in non-Hodgkin lymphomas irresponsive to chemotherapy. Leuk Res 2008; 32: 1183–1195.

Karran P . Mechanisms of tolerance to DNA damaging therapeutic drugs. Carcinogenesis 2001; 22: 1931–1937.

Christmann M, Tomicic MT, Kaina B . Phosphorylation of mismatch repair proteins MSH2 and MSH6 affecting MutSalpha mismatch-binding activity. Nucleic Acids Res 2002; 30: 1959–1966.

Hernandez-Pigeon H, Quillet-Mary A, Louat T, Schambourg A, Humbert O, Selves J et al. hMutS alpha is protected from ubiquitin-proteasome-dependent degradation by atypical protein kinase C zeta phosphorylation. J Mol Biol 2005; 348: 63–74.

Hernandez-Pigeon H, Laurent G, Humbert O, Salles B, Lautier D . Degradration of mismatch repair hMutSalpha heterodimer by the ubiquitin-proteasome pathway. FEBS Lett 2004; 562: 40–44.

Hegazy SA, Wang P, Anand M, Ingham RJ, Gelebart P, Lai R . The tyrosine 343 residue of nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) is important for its interaction with SHP1, a cytoplasmic tyrosine phosphatase with tumor suppressor functions. J Biol Chem 2010; 285: 19813–19820.

Zhang H, Richards B, Wilson T, Lloyd M, Cranston A, Thorburn A et al. Apoptosis induced by overexpression of hMSH2 or hMLH1. Cancer Res 1999; 59: 3021–3027.

Wu F, Wang P, Young LC, Lai R, Li L . Proteome-wide identification of novel binding partners to the oncogenic fusion gene protein, NPM-ALK, using tandem affinity purification and mass spectrometry. Am J Pathol 2009; 174: 361–370.

Wang P, Wu F, Zhang J, McMullen T, Young LC, Ingham RJ et al. Serine phosphorylation of NPM-ALK, which is dependent on the auto-activation of the kinase activation loop, contributes to its oncogenic potential. Carcinogenesis 2011; 32: 146–153.

Nicolaides NC, Littman SJ, Modrich P, Kinzler KW, Vogelstein B . A naturally occurring hPMS2 mutation can confer a dominant negative mutator phenotype. Mol Cell Biol 1998; 18: 1635–1641.

Armanious H, Gelebart P, Anand M, Belch A, Lai R . Constitutive activation of metalloproteinase ADAM10 in mantle cell lymphoma promotes cell growth and activates the TNFalpha/NFkappaB pathway. Blood 2011; 117: 6237–6246.

Blom N, Gammeltoft S, Brunak S . Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. J Mol Biol 1999; 294: 1351–1362.

Marra G, Iaccarino I, Lettieri T, Roscilli G, Delmastro P, Jiricny J . Mismatch repair deficiency associated with overexpression of the MSH3 gene. Proc Natl Acad Sci USA 1998; 95: 8568–8573.

Gibson SL, Narayanan L, Hegan DC, Buermeyer AB, Liskay RM, Glazer PM . Overexpression of the DNA mismatch repair factor, PMS2, confers hypermutability and DNA damage tolerance. Cancer Lett 2006; 244: 195–202.

Jiricny J . The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 2006; 7: 335–346.

Hickman MJ, Samson LD . Apoptotic signaling in response to a single type of DNA lesion, O(6)-methylguanine. Mol Cell 2004; 14: 105–116.

Acharya S, Wilson T, Gradia S, Kane MF, Guerrette S, Marsischky GT et al. hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6. Proc Natl Acad Sci USA 1996; 93: 13629–13634.

Plotz G, Raedle J, Brieger A, Trojan J, Zeuzem S . N-terminus of hMLH1 confers interaction of hMutLalpha and hMutLbeta with hMutSalpha. Nucleic Acids Res 2003; 31: 3217–3226.

Rasmussen LJ, Rasmussen M, Lee B, Rasmussen AK, Wilson DM 3rd, Nielsen FC et al. Identification of factors interacting with hMSH2 in the fetal liver utilizing the yeast two-hybrid system. In vivo interaction through the C-terminal domains of hEXO1 and hMSH2 and comparative expression analysis. Mutat Res 2000; 460: 41–52.

Li LS, Morales JC, Veigl M, Sedwick D, Greer S, Meyers M et al. DNA mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the potential for new therapeutic targets. Br J Pharmacol 2009; 158: 679–692.

Stoklosa T, Poplawski T, Koptyra M, Nieborowska-Skorska M, Basak G, Slupianek A et al. BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations. Cancer Res 2008; 68: 2576–2580.

Bellacosa A, Cicchillitti L, Schepis F, Riccio A, Yeung AT, Matsumoto Y et al. MED1, a novel human methyl-CpG-binding endonuclease, interacts with DNA mismatch repair protein MLH1. Proc Natl Acad Sci U S A 1999; 96: 3969–3974.

Mihaylova VT, Bindra RS, Yuan J, Campisi D, Narayanan L, Jensen R et al. Decreased expression of the DNA mismatch repair gene Mlh1 under hypoxic stress in mammalian cells. Mol Cell Biol 2003; 23: 3265–3273.

Warren JJ, Pohlhaus TJ, Changela A, Iyer RR, Modrich PL, Beese LS . Structure of the human MutSalpha DNA lesion recognition complex. Mol Cell 2007; 26: 579–592.

Ollila S, Sarantaus L, Kariola R, Chan P, Hampel H, Holinski-Feder E et al. Pathogenicity of MSH2 missense mutations is typically associated with impaired repair capability of the mutated protein. Gastroenterology 2006; 131: 1408–1417.

Ollila S, Dermadi Bebek D, Jiricny J, Nystrom M . Mechanisms of pathogenicity in human MSH2 missense mutants. Hum Mutat 2008; 29: 1355–1363.

Adamsen BL, Kravik KL, De Angelis PM . DNA damage signaling in response to 5-fluorouracil in three colorectal cancer cell lines with different mismatch repair and TP53 status. Int J Oncol 2011; 39: 673–682.

Aebi S, Fink D, Gordon R, Kim HK, Zheng H, Fink JL et al. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res 1997; 3: 1763–1767.

Kinsella TJ . Coordination of DNA mismatch repair and base excision repair processing of chemotherapy and radiation damage for targeting resistant cancers. Clin Cancer Res 2009; 15: 1853–1859.

O'Brien V, Brown R . Signalling cell cycle arrest and cell death through the MMR System. Carcinogenesis 2006; 27: 682–692.

Zeng X, Kinsella TJ . A novel role for DNA mismatch repair and the autophagic processing of chemotherapy drugs in human tumor cells. Autophagy 2007; 3: 368–370.

Stojic L, Cejka P, Jiricny J . High doses of SN1 type methylating agents activate DNA damage signaling cascades that are largely independent of mismatch repair. Cell Cycle 2005; 4: 473–477.

de las Alas MM, Aebi S, Fink D, Howell SB, Los G . Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance. J Natl Cancer Inst 1997; 89: 1537–1541.

Seifert M, Reichrath J . The role of the human DNA mismatch repair gene hMSH2 in DNA repair, cell cycle control and apoptosis: implications for pathogenesis, progression and therapy of cancer. J Mol Histol 2006; 37: 301–307.

Peters AC, Young LC, Maeda T, Tron VA, Andrew SE . Mammalian DNA mismatch repair protects cells from UVB-induced DNA damage by facilitating apoptosis and p53 activation. DNA Repair (Amst) 2003; 2: 427–435.

Young LC, Peters AC, Maeda T, Edelmann W, Kucherlapati R, Andrew SE et al. DNA mismatch repair protein Msh6 is required for optimal levels of ultraviolet-B-induced apoptosis in primary mouse fibroblasts. J Investig Dermatol 2003; 121: 876–880.

Young LC, Thulien KJ, Campbell MR, Tron VA, Andrew SE . DNA mismatch repair proteins promote apoptosis and suppress tumorigenesis in response to UVB irradiation: an in vivo study. Carcinogenesis 2004; 25: 1821–1827.

Adamson AW, Beardsley DI, Kim WJ, Gao Y, Baskaran R, Brown KD . Methylator-induced, mismatch repair-dependent G2 arrest is activated through Chk1 and Chk2. Mol Biol Cell 2005; 16: 1513–1526.

Wang Y, Qin J . MSH2 and ATR form a signaling module and regulate two branches of the damage response to DNA methylation. Proc Natl Acad Sci USA 2003; 100: 15387–15392.

Dierov J, Sanchez PV, Burke BA, Padilla-Nash H, Putt ME, Ried T et al. BCR/ABL induces chromosomal instability after genotoxic stress and alters the cell death threshold. Leukemia 2009; 23: 279–286.

Zhao R, Yang FT, Alexander DR . An oncogenic tyrosine kinase inhibits DNA repair and DNA-damage-induced Bcl-xL deamidation in T cell transformation. Cancer Cell 2004; 5: 37–49.

Skorski T . Oncogenic tyrosine kinases and the DNA-damage response. Nat Rev Cancer 2002; 2: 351–360.

Hallberg B, Palmer RH . Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer 2013; 13: 685–700.

Drummond JT, Genschel J, Wolf E, Modrich P . DHFR/MSH3 amplification in methotrexate-resistant cells alters the hMutSalpha/hMutSbeta ratio and reduces the efficiency of base-base mismatch repair. Proc Natl Acad Sci USA 1997; 94: 10144–10149.

Shcherbakova PV, Kunkel TA . Mutator phenotypes conferred by MLH1 overexpression and by heterozygosity for mlh1 mutations. Mol Cell Biol 1999; 19: 3177–3183.

Thông tin
Thông tin xuất bản

Blood Cancer Journal

Tập 5 Số 5

e311-e311

Thông tin tác giả